Diamyd Medical's CEO purchased shares in the Company
Diamyd Medical’s CEO Ulf Hannelius has purchased 20 000 Series B shares in Diamyd Medical. Hannelius’ holdings thus amount to 40 000 B-shares. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical trials are ongoing with Diamyd®. An exclusive license comprising the therapeutic use of